Humic substances in the healthcare industry

Mirza M.A.
Department of Pharmaceutics, SPER, Jamia Hamdard, New Delhi-110062
doi: 10.36291/HIT.2019.mirza.014

Currently humic substances are being marketed as non-prescription products in a range of categories across the globe. Different functionalities, potentials, abundance and low cost raw material of HS augur a future in therapeutic product category or in pharmaceutical excipient. But the way forward is not as easy as in case of non-prescription products (majorly safety and quality data needed). The associated impediments are,

– requirement of full battery of safety and efficacy data (depending upon claims and categories of the products);
– availability of consistent quality raw material;
– full chemical and analytical characterization;
– low yield and consumption of by-product;
– not well recognized by regulatory agencies.

So, it requires a consorted effort by different stake holders of product development. If planned meticulously, it can also be dealt in a collaborative fashion with experts of specific fields in fine tuning with regulatory requirements. The invited talk would touch upon these nuances in details.